District Of Columbia is currently home to 861 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
NCT04890093
Recruiting
Background: The drug PEN-866 can remain in tumor cells longer than it does in normal cells. It also may be more effective than other drugs at treating Ewing sarcoma and rhabdomyosarcoma. Researchers want to learn if combining PEN-866 with other drugs can treat certain cancers in adolescents and young adults. Objective: To learn if the combination of PEN-866 with vincristine and temozolomide can be used to treat adolescents and young adults with solid tumors that have returned after or did not... Read More
Gender:
ALL
Ages:
Between 12 years and 39 years
Trial Updated:
04/12/2025
Locations: Childrens National Medical Center, Washington, District of Columbia
Conditions: Sarcoma, Ewing, Rhabdomyosarcoma
Register for Updates
ASSESS ALL ALS Study
NCT06578195
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Georgetown University, Washington, District of Columbia
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
NCT05928806
Recruiting
This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. The study will plan to enroll 120 eligible patients randomized in a 2:1 fashion to Arm A and Arm B. Patients in all IMDC Risk Groups are included. This study utilizes a Simon's two stage design which is describ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Georgetown University, Washington, District of Columbia
Conditions: Advanced Renal Cell Carcinoma
Register for Updates
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
NCT04978727
Recruiting
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. SurVaxM is designed to tell the body's immune system to look for tumor cells that express a protein called survivin and destroy them. The survivin protein can be found on up to 95% of glioblastomas and other types of cancer but is not found in normal cells. If the body's immune system knows to destroy cells that express surviv... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/11/2025
Locations: Children's National, Washington, District of Columbia
Conditions: Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Register for Updates
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 28 days and 18 years
Trial Updated:
04/11/2025
Locations: Research Site #104, Washington, District of Columbia
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877
Recruiting
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: The George Washington University, Washington, District of Columbia
Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705
Recruiting
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Obstructive Hypertrophic Cardiomyopathy
Register for Updates
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
NCT05040178
Recruiting
To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®.
Gender:
ALL
Ages:
All
Trial Updated:
04/10/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Hyperammonemia, Methylmalonic Acidemia, Propionic Acidemia
Register for Updates
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033
Recruiting
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Sibley Memorial Hospital - a member of Johns Hopkins medicine, Washington, District of Columbia
Conditions: Locally Advanced Pancreatic Cancer
Register for Updates
Pre-operative Hypofractionated Proton Therapy
NCT05917301
Recruiting
This study is being done to examine whether proton therapy for certain kinds of sarcomas (extremity and trunk soft tissue) is safe and effective. As part of the study, patients will have five fractions of proton therapy before the participants have surgery for the sarcoma. The study will measure wound complications and functional outcomes / quality of life after the procedures. Patients will be asked to complete questionnaires about the treatment and quality of life from the time of enrollment... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Soft Tissue Sarcoma
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 4
NCT05617014
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/09/2025
Locations: Georgetown University, Washington, District of Columbia
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
Register for Updates
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
NCT05318573
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Register for Updates